Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Trisha Babcock"'
Autor:
Thomas Bott, Nanor Bozoyan, Trisha Babcock, Kristen Cushman, Akanksha Sharma, Naveed Wagle, Jose Carrillo, Tiffany Juarez, Santosh Kesari
Publikováno v:
Neuro-Oncology. 24:vii240-vii240
INTRODUCTION ClinicalPath is an evidence-based oncology decision support and analytics tool for cancer care. ClinicalPath’s treatment recommendations are prioritized based on efficacy, toxicity, and cost by a nationwide committee of oncologists. Th
Autor:
Matthew D. Silva, Cindy Q. Xia, Panos Hatsis, Erik Kupperman, Li Yu, Jennifer Terkelsen, Mark Williamson, Yueying Cao, Trisha Babcock, Robbie Robertson, Bret Bannerman
Publikováno v:
Molecular cancer therapeutics. 8(12)
Understanding a compound's preclinical pharmacokinetic, pharmacodynamic, and efficacy relationship can greatly facilitate its clinical development. Bortezomib is a first-in-class proteasome inhibitor whose pharmacokinetic/pharmacodynamic parameters a
Autor:
Yu Jie, Julie Zhang, Yu Yang, Erik Kupperman, Mark Fleming, Yueying Cao, Doug Bowman, Jill Donelan, Bradley Stringer, Trisha Babcock, Allison Berger, Eric S. Lightcap, Edmund Lee
Publikováno v:
Molecular Cancer Therapeutics. 8:B40-B40
The ubiquitin-proteasome system processes the majority of cellular proteins and is the principal pathway by which cells regulate protein homeostasis. The successful development of VELCADE® (bortezomib) for Injection for multiple myeloma and previous
Autor:
Jill Donelan, David I. Lichter, Paul Hales, Erik Koenig, Kristen Bano, Laura Faron-Yowe, Bradley Stringer, Hadi Danaee, Bret Bannerman, Kristin E. Burke, Trisha Babcock, Erik Kupperman
Publikováno v:
Blood. 114:3724-3724
Abstract 3724 Poster Board III-660 Lymphomas account for about 5% of all cases of cancer in the US. In 2009, it is estimated that 74490 Americans will be diagnosed with lymphoma, which includes approximately 8510 new cases of Hodgkin's lymphoma and 6